MCL: first-line VR-CAP delivers deep, durable response vs R-CHOP
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Patients with newly diagnosed mantle cell lymphoma (MCL) achieved deeper, more durable responses with first-line VR-CAP (bortezomib [Revlimid], rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) vs R-CHOP (rituximab [Rituxan] plus cyclophosphamide, vincristine, doxorubicin, and prednisone).
Why this matters
In the primary analysis of the LYM-3002 study, VR-CAP delivered 59% improvement vs R-CHOP in median PFS by independent radiology review.
Analysis of the LYM-3002 phase 3 study to investigate the association between improved outcomes and response associated first-line R-CAP vs R-CHOP in 487 patients with newly diagnosed MCL.
243 patients received VR-CAP, 244 received R-CHOP; 229 and 228 patients, resp...